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Anti-Ischemic Properties of
Calcium-Channel Blockers
Lessons From Cardiac Surgery*
Lionel H.Opie, MD, FACC, FRCP, DPHIL, DSC
Cape Town, South Africa
Calcium-channel blocking agents (CCBs) (or calcium an-
tagonists) were originally introduced to counteract myocar-
dial ischemia and, in particular, angina pectoris. It was only
later that their antihypertensive qualities came to be under-
stood and commercially exploited. About 25 years ago,
when the calcium-induced coronary spasm theory of unsta-
ble angina was dominant, short-acting CCBs were among
the most widely used antianginal agents in the world.
Gradually, arguments for evidence-based medicine were
coming. In a decisive trial, the Holland Inter-university
Nifedipine Trial (HINT) study in unstable angina (1),
therapy by short-acting nifedipine led to an increased rate of
recurrent myocardial infarction (MI), so the trial was
stopped. However, in a tantalizing way, the beta-blocker
arm of the study did not show a significant improvement,
and it was only the combination of the two different classes
of drugs that gave the desired decrease in repeat MI.
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Thereafter, it was clearly unethical to use this subtype of
CCBs, namely the short-acting dihydropyridines (DHPs),
without concurrent beta-blockade for unstable angina. With
the non-DHPs such as diltiazem and verapamil, which also
slowed the heart rate, the situation was different in that a
number of smaller trials showed benefit (2). Taking together
the available studies, there were good arguments for two
different types of antianginal mechanisms: beta-blockade,
acting chiefly by the inhibitory effects on heart rate and
cardiac contractility, with CCBs acting chiefly as coronary
vasodilators and the non-DHPs having intermediate prop-
erties (3).
Major surgery is an inevitably stress-provoking procedure
with increased adrenergic discharge, as shown by the ben-
eficial effects of beta-blocker therapy covering noncardiac
surgery (4). Many episodes of perioperative ischemia are
silent and occur especially in the postoperative period, often
with a tachycardia (5). Therefore, logically, the anti-
ischemic agents of choice should be beta-blockers. Regard-
ing the non-DHP calcium channel blockers, their use in the
perioperative period is logical considering that they have
heart rate reducing properties and, like beta-blockers, have
negative inotropic and dromotropic effects. The DHPs, on
the other hand, lack these properties, and in fact, some may
increase the heart rate. Thus, it could be argued that DHPs
should not give perioperative protection. However, they do
have coronary vasodilatory properties with the potential for
perioperative protection.
QUALITY OF THE PRESENT STUDY
Therefore, the studies by Wijeysundera et al. (6) in the issue
of the Journal are of special interest. They searched the
literature for randomized controlled trials (RCTs) relating
to CCBs and their effects on complications of cardiac
surgery such as death, MI, ischemia, and supraventricular
tachycardias. Their literature search for data to include in
this meta-analysis followed the Quality of Reporting of
Meta-analyses (QUOROM) guidelines destined to improve
the quality of reports of meta-analyses (7). Out of the
potential 1,813 studies, they eventually selected 41 studies
for their meta-analysis. Of these, 28 studies related to
intraoperative complications or those occurring during the
first postoperative day. Other studies were for longer peri-
ods. Approximately one-half were given DHP therapy,
mostly intravenous nifedipine or nicardipine; the rest were
given either diltiazem or verapamil.
The rigorous inclusion process relied on quality grading
using the Jadad et al. (8) scoring system, which assesses the
quality of RCTs chiefly on three prime qualities: 1) the
adequacy of randomization; 2) the quality of the double-
blinding; and 3) the exactness of follow-up, with particular
reference to withdrawals and dropouts (Table 1). Thus,
patients included in any given study but not completing the
observation period or those who are not included in the
analysis must be described. The number and reasons for
withdrawal in each group must also be stated. To enter the
present study required a minimum Jadad score of 1. The
primary analyses were approached in a conventional way,
with secondary analyses for each CCB class, with compar-
isons of CCBs versus nitroglycerine and for those who
underwent CABG alone. Thereafter followed sensitivity
analyses by successively withdrawing trials of the most
favorable CCB treatment effects. Furthermore, the authors
repeated the meta-analyses for different Jadad scores, and
funnel tests were performed to counter any possible publi-
cation bias.
Using all these precautions, CCBs reduced MI with an
odds ratio (OR) of 0.58 and confidence interval (CI) of 0.37
to 0.91. They reduced ischemia with an OR of 0.53 and CI
of 0.39 to 0.72. Non-DHPs reduced supraventricular tachy-
cardias with an OR of 0.60 and CI of 0.41 to 0.93.
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Regarding the small numbers of deaths, there was no trend
to increased mortality, but rather towards a decrease.
Where does this place us at a time when beta-blockers are
generally thought to be the agents of choice to cover
perioperative ischemia (4)? Before making such compari-
sons, we are entitled to ask how convincing this new
evidence is.
THE STRENGTH OF A META-ANALYSIS
Even RCTs and meta-analyses are not free of defects and
need careful design and critical appraisal. A meta-analysis is
only as good as the studies that it analyzes, even when full
precautions to obtain best results have been taken, as in the
present study. Yet despite all the efforts of the authors, and
including the QUOROM and Jadad criteria, the present
study does fall short of the ideal (Table 1), chiefly because of
the nature of the limited database. Of note, in none of the
individual studies in the present meta-analysis were more
than 221 subjects studied. Ideally, to achieve a satisfactory
meta-analysis requires studies each with 1,000 patients or
more (9). Most of the studies are much smaller, and in the
present one, in total, there were only 480 patients with high
Jadad scores (3 or more). Therefore, although a major
contribution, this meta-analysis does not clearly and un-
equivocally show that CCBs confer benefits when given in
association with cardiac surgery. The authors are quite
correct in emphasizing that further prospective studies are
needed to determine the true effects of CCBs on outcome
measures, particularly including perioperative mortality.
Postoperative atrial fibrillation should be a further specific
outcome measure, especially bearing in mind the docu-
mented success of beta-blockers in preventing this compli-
cation (10).
Regarding items 4 and 5 of the ideal meta-analysis as
shown in Table 1, two major publications have had statis-
tical errors that, although not wrong regarding the direction
of change, did mislead readers regarding the magnitude of
the change (11,12). Both required corrections. I must
confess to being author of one of the articles with errors
(12), after having criticized another article for the exact
same reason (11). Also, in any controversial area, such as
safety or efficacy of the CCBs, personal bias may creep in, so
that the technique of blinded assessment of data in various
studies as recommended by Jadad et al. (8) and as used by
the present authors seems ideal. However, the complete
ideal would be to have the final statistics and data checked
by an external blinded statistician.
CCBs AS ANTI-ANGINAL AGENTS
Although CCBs were originally introduced for angina, their
use has suffered with the advance of beta-blockade. The
present studies show clearly that they have anti-ischemic
properties. When the American College of Cardiology/
American Heart Association Committee drew up its rec-
ommendations on drug use for angina (13), in my opinion,
it short-changed the CCBs and, in particular, virtually
ignored amlodipine (14). Of the 74 trials in the Stanford
meta-analysis (15) that the Committee cited and heavily
relied on, hardly any related to amlodipine, arguably the
most widely used of the CCBs. If CCBs are such effective
anti-ischemic drugs as the present meta-analysis would
suggest, then their role in stable-effort angina may need to
be reconsidered (14). In general, the important study by
Table 1. Properties of an Ideal Meta-Analysis
Ideal Requirements Present Study
1. Database Based on an adequate number of randomized
controlled trials, each having 1,000 or
more subjects.
Based on 41 studies on 3,327 patients. However,
largest individual study on only 211 patients.
2. Overall quality of meta-analysis QUOROM recommendations for trial flow
and inclusion and exclusion of studies (7).
Followed QUOROM recommendations for trial
flow and exclusion of studies. Data carefully
assessed by blinded observers. Started with
1,813 trials, most excluded by screening of
title and abstracts. Of 79 trials left, selected
41, most of those excluded by poor end point
data.
3. Specific requirements for included data High Jadad score chiefly based on three
requirements (8). First, the adequacy of
randomization; second, high quality
double-blinding; third, exact follow-up
with particular reference to withdrawals
and dropouts.
Minimal Jadad score of 1 of 5. Not three items,
nor clear which five. Sensitivity analysis
showed similar results for low and high Jadad
scores. Funnel plots to avoid publication bias.
4. Conflicts of interest The authors of meta-analyses should be
nonbiased and have minimal or no
conflicts of interest in controversial areas.
No conflicts declared.
5. Check on statistics presented Authors must take responsibility for
statistical accuracy; ideally need
independent blinded check. Readers take
results on trust.
Selection of studies and early evaluation blinded,
but final statistics presumed valid without
independent check.
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Rinaldi et al. (16) seems to have been overlooked. In that
study, not only was the antianginal effect of the CCB
amlodipine versus nitrate on the onset of effort angina
evaluated and found equal, but particular attention was paid
to the post-ischemic recovery after exercise cessation. De-
layed recovery is an index of post-ischemic stunning with a
temporary fall in cardiac output and transiently impaired
exercise capacity. At 30 min after exercise, amlodipine
attenuated stunning with increased shortening and ejection
fraction and with more rapid isovolumic relaxation. The
anginal attack is not over until the patient can again exercise
normally. Yet postexercise recovery is very seldom an end
point of anginal studies. Data with amlodipine suggest that
enhanced postischemic recovery is a property of CCBs and
an important although neglected aspect of antianginal
therapy.
Of course, short-term benefit against angina does not
equal long-term outcome benefit. The Stanford meta-
analysis had to acknowledge that there were no good
long-term data to distinguish between beta-blockers and
calcium blockers (15). That meta-analysis, based on the
small number of hard outcome events in stable angina, could
not exclude a long-term benefit or harm of CCBs versus
beta-blockers. Recently, the CCB lacidipine was compared
with atenolol, the entry point being carotid disease (an index
of generalized arterial disease) in the presence of hyperten-
sion (17). Again, outcome data, although limited, suggested
equality between these two types of drugs with, in this case,
possibly better outcome with the CCB.
GENERAL COMMENTS ON
SAFETY AND EFFICACY OF CCBS
In general, CCBs have gone through different phases. First
they were hailed as very effective antianginals and then as
equally effective antihypertensives. However, the reflex
tachycardia induced by short-acting nifedipine was ignored
and is the probable explanation for the adverse effects found
by Furberg et al. (11) when they studied the effects on
mortality of short-acting nifedipine given in very high doses
to patients largely with unstable coronary disease. Although
his results were disputed by many, including myself and
Messerli (18), and although there were indeed errors in the
calculation, nonetheless Furberg et al. (11) correctly pointed
out the need for large RCT studies with CCBs. Some of
those studies have now come in: for example, the Interven-
tion as a Goal in Hypertension Treatment (INSIGHT)
study, comparing long-acting slow-release nifedipine versus
a potassium-retaining diuretic in the management of hyper-
tension (19). There were approximately equal primary
outcome benefits, although the CCBs gave rise to less
diabetes, gout, and cholesterol elevation, whereas the di-
uretic gave rise to less heart failure.
Regarding angina, the results of the ACTION (A Cor-
onary disease Trial Investigating Outcome with Nifedipine
GITS) study are still to come (20). This study evaluates the
effect of added long-acting nifedipine to pre-existing ther-
apy in angina of effort. So far a large number of patients
have been enrolled, more than 6,000, and the safety com-
mittee has allowed the study to proceed. Likewise in the
giant study ALLHAT (Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial) (21),
the CCB arm gave overall results similar to the diuretic.
This study has given further insights into the efficacy and
safety of the DHP CCBs, at least in high-risk hypertension.
Yet the comparison between amlodipine and chlorthalidone
in ALLHAT gave results similar to that between long-
acting nifedipine and amiloride-thiazide in INSIGHT (19).
In both studies more heart failure with the CCB was
balanced by less new diabetes.
Thus, the present surgical study fits into a general
pattern: CCBs have anti-ischemic properties for which they
can safely be used, without there being sufficient long-term
hard outcome data to be sure of effects on mortality. Such
data are going to be hard to harvest. It is appropriate to
recall that among three major meta-analyses of outcome
when CCBs were used for hypertension, all agree that there
were no differences in major cardiac events or total mortality
when CCBs were compared with conventional therapy by
diuretics and/or beta-blockers (12,22,23). Thus, jumping
from the present surgical study to the wider implications,
this meta-analysis provides further data favoring the view
that CCBs are both effective and safe drugs when correctly
used with due respect for their properties, indications, and
limitations. The specific message of the present meta-
analysis is quite clear: CCBs may be safer and have more
benefit in cardiac surgery than often supposed.
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